← Browse by Condition
Medical Condition
metastatic lung non small cell carcinoma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for metastatic lung non small cell carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — metastatic lung non small cell carcinoma Clinical Trials
How many clinical trials are currently recruiting for metastatic lung non small cell carcinoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for metastatic lung non small cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic lung non small cell carcinoma?
metastatic lung non small cell carcinoma research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic lung non small cell carcinoma clinical trial?
Eligibility criteria for metastatic lung non small cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Top Sponsors
3 trials
1 trial
1 trial
Recruiting Clinical Trials
NCT06472804
Recruiting
Insomnia in Patients With Metastatic Lung Cancer
Enrollment
60 pts
Location
United States
Sponsor
Mayo Clinic
NCT06349642
Recruiting
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Enrollment
324 pts
Location
United States
Sponsor
Mayo Clinic
NCT07017829 Phase 2
Recruiting
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Enrollment
28 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
NCT05786924 Phase 1, Phase 2
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Enrollment
554 pts
Location
United States, Japan
Sponsor
Institut de Recherches Interna...
NCT05269381 Phase 1, Phase 2
Recruiting
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Enrollment
132 pts
Location
United States
Sponsor
Mayo Clinic
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology